Publications by authors named "Nicholas Gross"

Claim this Profile
S
Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease.
Samuel Frank, Claudia M Testa, Jody Goldstein, Elise Kayson, Blair R Leavitt, Nicholas Gross

CNS Drugs· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
Robert A Hauser, Hadas Barkay, Hubert H Fernandez, Joohi Jimenez-Shahed, Stewart A Factor, Nicholas Gross

J Clin Psychopharmacol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multinational, drug utilization study of lipegfilgrastim use in real-world setting in Europe.
Sigal Kaplan, Dana Ilic Bogojevic, Carolyn Rainville, Nicholas Gross

Support Care Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.
Samuel Frank, Claudia Testa, Mary C Edmondson, Jody Goldstein, Elise Kayson, Nicholas Gross

CNS Drugs· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia.
Martha Sajatovic, Stacy Finkbeiner, Amanda Wilhelm, Hadas Barkay, Nayla Chaijale, Nicholas Gross

Am J Geriatr Psychiatry· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.
Robert A Hauser, Hadas Barkay, Hubert H Fernandez, Stewart A Factor, Joohi Jimenez-Shahed, Nicholas Gross

Front Neurol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor Devices.
Mark Forrest Gordon, Igor D Grachev, Itzik Mazeh, Yonatan Dolan, Ralf Reilmann, Nicholas Gross

Digit Biomark· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.
Anne C Baakman, Rob Zuiker, Joop M A van Gerven, Nicholas Gross, Ronghua Yang

Br J Clin Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
Ralf Reilmann, Andrew McGarry, Igor D Grachev, Juha-Matti Savola, Beth Borowsky, Nicholas Gross

Lancet Neurol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.
Donald P Tashkin, Nicholas J Gross

Int J Chron Obstruct Pulmon Dis· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The COPD Pipeline XXXX.
Nicholas Gross

Chronic Obstr Pulm Dis· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mode of action of anticholinergics in asthma.
Reinoud Gosens, Nicholas Gross

Eur Respir J· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Broadband longwave radio remote sensing instrumentation.
Morris B Cohen, Ryan K Said, Evans W Paschal, Jackson C McCormick, Nicholas C Gross

Rev Sci Instrum· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The COPD Pipeline XXXVII.
Nicholas Gross

Chronic Obstr Pulm Dis· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The COPD Pipeline XXXVIII.
Nicholas Gross

Chronic Obstr Pulm Dis· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The COPD Pipeline XXXIX.
Nicholas Gross

Chronic Obstr Pulm Dis· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The COPD Pipeline XXXVI.
Nicholas Gross

Chronic Obstr Pulm Dis· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The COPD Pipeline XXXV.
Nicholas Gross

Chronic Obstr Pulm Dis· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The COPD Pipeline XXXIV.
Nicholas Gross

Chronic Obstr Pulm Dis· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Therapies for Asthma and Chronic Obstructive Pulmonary Disease.
Nicholas J Gross, Peter J Barnes

Am J Respir Crit Care Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nebulized Long-Acting Beta2-Agonists: More Than Just Bridging Gaps in the Management of Symptomatic COPD.
Daniel A Gerardi, Nicholas J Gross

Chronic Obstr Pulm Dis· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The COPD Pipeline XXXIII.
Nicholas Gross

Chronic Obstr Pulm Dis· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The COPD Pipeline XXXII.
Nicholas Gross

Chronic Obstr Pulm Dis· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study.
Terence A Ketter, Jess Amchin, Mark A Frye, Nicholas Gross

J Affect Disord· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The COPD Pipeline XXXI.
Nicholas Gross

Chronic Obstr Pulm Dis· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis